At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Peginterferon Alpha-2adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of Peginterferon Alpha-2a Maintenance Therapy on Portal Hypertension in Patients With Chronic Hepatitis C Virus Infection and Advanced Fibrosis and Cirrhosis Enrolled in the HALT-C Trial
In Brief
A clinical study evaluating Peginterferon Alpha-2a for Hepatitis C and 2 related conditions. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Cirrhosis, Fibrosis
CountriesUnited States
CollaboratorsRoche Pharma AG
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedNov 2005
Primary CompletionSep 2007
TodayJul 2026
First PostedNov 11, 2005
Enrollment StartNov 1, 2005
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.6 years ago
Interventions
Peginterferon Alpha-2adrug